Literature DB >> 25687401

A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

M E Schutzer1, P F Orio2, M C Biagioli3, D A Asher4, H Lomas1, D Moghanaki5.   

Abstract

Permanent radioactive seed implantation provides highly effective treatment for prostate cancer that typically includes multidisciplinary collaboration between urologists and radiation oncologists. Low dose-rate (LDR) prostate brachytherapy offers excellent tumor control rates and has equivalent rates of rectal toxicity when compared with external beam radiotherapy. Owing to its proximity to the anterior rectal wall, a small portion of the rectum is often exposed to high doses of ionizing radiation from this procedure. Although rare, some patients develop transfusion-dependent rectal bleeding, ulcers or fistulas. These complications occasionally require permanent colostomy and thus can significantly impact a patient's quality of life. Aside from proper technique, a promising strategy has emerged that can help avoid these complications. By injecting biodegradable materials behind Denonviller's fascia, brachytherpists can increase the distance between the rectum and the radioactive sources to significantly decrease the rectal dose. This review summarizes the progress in this area and its applicability for use in combination with permanent LDR brachytherapy.

Entities:  

Mesh:

Year:  2015        PMID: 25687401     DOI: 10.1038/pcan.2015.4

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  99 in total

1.  Prostatorectal fistula 14 years following brachytherapy for prostate cancer.

Authors:  J W Davis; P F Schellhammer
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

2.  Efficacy and complications of argon plasma coagulation for hematochezia related to radiation proctopathy.

Authors:  Raphael T Villavicencio; Douglas K Rex; Emad Rahmani
Journal:  Gastrointest Endosc       Date:  2002-01       Impact factor: 9.427

3.  Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.

Authors:  Jinesh N Shah; Ronald D Ennis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-16       Impact factor: 7.038

4.  I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.

Authors:  Andrew Herstein; Kent Wallner; Gregory Merrick; Hiroki Mitsuyama; Julius Armstrong; Lawrence True; William Cavanagh; Wayne Butler
Journal:  Cancer J       Date:  2005 Sep-Oct       Impact factor: 3.360

5.  High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.

Authors:  D Jeffrey Demanes; Alvaro A Martinez; Michel Ghilezan; Dennis R Hill; Lionel Schour; David Brandt; Gary Gustafson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-09       Impact factor: 7.038

6.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Authors:  M J Zelefsky; T Hollister; A Raben; S Matthews; K E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

7.  Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.

Authors:  Tracy Sherertz; Kent Wallner; Gregory Merrick; Eric Ford; Steven Sutlief; William Cavanagh; Wayne Butler; Lawrence True
Journal:  Brachytherapy       Date:  2004       Impact factor: 2.362

8.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

9.  Argon plasma coagulation in chronic radiation proctitis.

Authors:  A Postgate; B Saunders; J Tjandra; J Vargo
Journal:  Endoscopy       Date:  2007-04       Impact factor: 10.093

10.  Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.

Authors:  Al V Taira; Gregory S Merrick; Robert W Galbreath; Kent E Wallner; Wayne M Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-19       Impact factor: 7.038

View more
  4 in total

1.  Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy.

Authors:  Jeremiah W Sanders; Rajat J Kudchadker; Chad Tang; Henry Mok; Aradhana M Venkatesan; Howard D Thames; Steven J Frank
Journal:  Radiol Artif Intell       Date:  2022-01-26

Review 2.  Chronic radiation proctitis: tricks to prevent and treat.

Authors:  Ben G L Vanneste; Lien Van De Voorde; Rogier J de Ridder; Evert J Van Limbergen; Philippe Lambin; Emile N van Lin
Journal:  Int J Colorectal Dis       Date:  2015-07-23       Impact factor: 2.571

Review 3.  Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.

Authors:  Nicholas A Serrano; Noah S Kalman; Mitchell S Anscher
Journal:  Cancer Manag Res       Date:  2017-07-28       Impact factor: 3.989

4.  Laparoscopic Allograft Spacer Placement to Minimize Bowel Dose During Re-irradiation with Interstitial Brachytherapy.

Authors:  Shraddha Dalwadi; Anuj Suri; Aparna Kamat; E Brian Butler; Andrew M Farach
Journal:  Cureus       Date:  2019-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.